Intensity Therapeutics (INTS), with a ~$13M market cap, closed up nearly 395% Thursday after publishing phase 1/2 results on ...

Cancer immunotherapy, especially using T cells, is showing a lot of promise in treating blood cancers. Bioengineered T cells, ...

Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc.

An investigator presented results from a pre-specified primary efficacy analysis of the phase 2 EXTEND trial testing the progression-free survival (PFS) benefits of metastasis-directed therapy by ...

A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

An international collaboration of researchers, including Imperial College London and UCLA, has developed a collagen-binding ...

A research team of Lee Je-joong and Jung Sung-hoon and Dr. Lee Min-geun of the Department of Hematology at Hwasun Chonnam ...

Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this ...

Recognized in the Healthcare category of the 2025 Top Innovations contest, Haystack MRD® enables minimal residual disease ...

The integration of single-cell RNA sequencing (scRNA-seq) with AI has become a cornerstone for deciphering tumor heterogeneity. For instance, in pancreatic ductal adenocarcinoma (PDAC), spatial ...

Tumors adapt to their environment to avoid detection. As different cancer treatments progress, tumors mutate and become resistant. Various markers are expressed on tumors that can be used to target in ...

Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the ...